Ozempic may have a stronger rival. An experimental weekly injection – Eli Lilly’s “retatrutide” – may be the most potent weight-loss drug yet. In a new trial, it helped people with type 2 diabetes lose an average of 20 kg, more than double the loss with Ozempic.
Retatrutide isn’t yet approved anywhere in the world, India included. Lilly announced the results of TRANSCEND-T2D-2, a Phase 3 trial, on October 28. Phase 3 is the last stage of testing before a company asks regulators for approval. This is the first time retatrutide has been tested directly, or “head-to-head”, against an existing drug of its kind instead of a dummy injection.